Skip to Content
Merck
CN
All Photos(1)

Documents

1478800

USP

Orlistat

United States Pharmacopeia (USP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
(−)-Tetrahydrolipstatin, N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester, Ro-18-0647
Empirical Formula (Hill Notation):
C29H53NO5
CAS Number:
96829-58-2
Molecular Weight:
495.73
MDL number:
MFCD05662360
UNSPSC Code:
41116107
PubChem Substance ID:
329750618
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

orlistat

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O

InChI

1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1

InChI key

AHLBNYSZXLDEJQ-FWEHEUNISA-N

Gene Information

human ... LIPF(8513) , PNLIP(5406)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem/physiol Actions

Orlistat, used in obesity research, is a pancreatic lipase inhibitor that acts locally in the gastrointestinal tract to inhibit lipase.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Solution is not completely clear, small particles may remain floating.
Sales restrictions may apply.

related product

Product No.
Description
Pricing

1478833

Orlistat Related Compound C, United States Pharmacopeia (USP) Reference Standard

1478811

Orlistat Related Compound A, United States Pharmacopeia (USP) Reference Standard

1478844

Orlistat Related Compound D, United States Pharmacopeia (USP) Reference Standard

1478855

Orlistat Related Compound E, United States Pharmacopeia (USP) Reference Standard

1478822

Orlistat Related Compound B, United States Pharmacopeia (USP) Reference Standard

1680685

Tributyl phosphine oxide, United States Pharmacopeia (USP) Reference Standard

PHR2544

Orlistat Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2543

Orlistat Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sheridan Henness et al.
Drugs, 66(12), 1625-1656 (2006-09-08)
Orlistat (Xenical) is a reversible inhibitor of gastric and pancreatic lipases. In conjunction with a hypocaloric diet and moderate exercise, orlistat is an effective drug for use in the management of obesity in adults with or without comorbidities. Recent data
Walmir Coutinho
Arquivos brasileiros de endocrinologia e metabologia, 53(2), 262-270 (2009-05-26)
Ancillary therapies for weight management, consisting mainly of diet and exercise programs that incorporate variable levels of lifestyle modification techniques, are frequently ineffective to achieve clinically meaningful weight loss and maintenance. Although pharmacological treatment of obesity is widely used in
György Paragh et al.
Orvosi hetilap, 146(11), 493-498 (2005-04-09)
The overweight and obesity represent severe problems for the health management system of developed countries. In the evolution of obesity, beside genetic background, the environmental factors also play important roles. In the daily routine, the majority of obese patients need
James W Anderson
Expert opinion on pharmacotherapy, 8(11), 1733-1742 (2007-08-10)
Orlistat, in the 60-mg over-the-counter dose, was recently approved by the FDA. This lipase inhibitor blocks absorption of ~25% of ingested fat and has ~85% of the efficacy of the 120-mg dose for weight loss. Over 16 weeks weight loss
Belinda S Drew et al.
Vascular health and risk management, 3(6), 817-821 (2008-01-19)
Over the past 20 years obesity has become a worldwide concern of frightening proportion. The World Health Organization estimates that there are over 400 million obese and over 1.6 billion overweight adults, a figure which is projected to almost double
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service